Anaptysbio (ANAB) Non Operating Income (2016 - 2026)
Anaptysbio (ANAB) posted Non Operating Income of -$18.2 million for Q1 2026, down 5.82% on a QoQ basis from -$17.2 million in Q4 2025, and down 55.01% year-over-year from -$40.5 million in Q1 2025.
Anaptysbio (ANAB) Non Operating Income (2016 - 2026) Analysis & Trends
Anaptysbio's Non Operating Income history runs 11 years deep, the most recent figure standing at -$18.2 million for Q1 2026.
- Quarterly Non Operating Income fell 55.01% year-over-year to -$18.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$67.4 million (down 67.35% YoY) and the FY2025 annual result came in at -$61.0 million, down 101.34% from the prior year.
- Non Operating Income was -$18.2 million for Q1 2026 at Anaptysbio, down from -$17.2 million in the prior quarter.
- Across five years, Non Operating Income topped out at $424000.0 in Q3 2023 and bottomed at -$19.6 million in Q3 2025.
- A 5-year average of -$7.2 million and a median of -$4.8 million in 2022 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2023 — Non Operating Income soared 110.96% — and 2024, when it tumbled 15050.0%.
- Anaptysbio's Non Operating Income stood at -$416000.0 in 2022, then jumped by 80.77% to -$80000.0 in 2023, then tumbled by 15050.0% to -$12.1 million in 2024, then plunged by 41.96% to -$17.2 million in 2025, then declined by 5.82% to -$18.2 million in 2026.
- Business Quant data shows ANAB's Non Operating Income at -$18.2 million in Q1 2026, -$17.2 million in Q4 2025, and -$19.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 444,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -8.59 Mn |
| 10 | Anaptysbio | 1.55 Bn | 1.27 Bn | - | -18.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.21 Mn |
| Dec 31, 2025 | -17.21 Mn |
| Sep 30, 2025 | -19.59 Mn |
| Jun 30, 2025 | -12.42 Mn |
| Mar 31, 2025 | -11.75 Mn |
| Dec 31, 2024 | -12.12 Mn |
| Sep 30, 2024 | -10.09 Mn |
| Jun 30, 2024 | -6.33 Mn |
| Mar 31, 2024 | -1.74 Mn |
| Dec 31, 2023 | -80,000.00 |
| Sep 30, 2023 | 424,000.00 |
| Jun 30, 2023 | 298,000.00 |
| Mar 31, 2023 | 146,000.00 |
| Dec 31, 2022 | -416,000.00 |
| Sep 30, 2022 | -3.87 Mn |
| Jun 30, 2022 | -4.76 Mn |
| Mar 31, 2022 | -4.51 Mn |
| Dec 31, 2021 | -1.38 Mn |
| Sep 30, 2021 | 97,000.00 |
| Jun 30, 2021 | 104,000.00 |